New drugs and new toxicities: pembrolizumab-induced myocarditis

Pembrolizumab is an immune checkpoint inhibitor that significantly improves clinical outcomes in numerous solid organ malignancies. Despite successful therapeutic responses, this new drug comes with a constellation of adverse reactions. Herein, we chronicle the case of a patient with metastatic non-...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:BMJ Case Rep
Asıl Yazarlar: Inayat, Faisal, Masab, Muhammad, Gupta, Sorab, Ullah, Waqas
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2018
Konular:
Unexpected Outcome (Positive or Negative) Including Adverse Drug Reactions
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5787012/
https://ncbi.nlm.nih.gov/pubmed/29367376
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2017-223252
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller